GNFT NIS2+ validated as scalable non-invasive MASH diagnostics solution
TradingView News says NIS2+ has been validated as a scalable, non-invasive test aimed at unlocking the MASH diagnostic and monitoring market, supported by pharma partnerships.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.